Comparative Pharmacology
Head-to-head clinical analysis: ALPHAGAN versus APRACLONIDINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHAGAN versus APRACLONIDINE HYDROCHLORIDE.
ALPHAGAN vs APRACLONIDINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Alpha-2 adrenergic receptor agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
1 drop of 0.1% or 0.15% solution in the affected eye(s) three times daily, approximately 8 hours apart.
1-2 drops of 0.5% or 1% solution in the affected eye(s) three times daily.
None Documented
None Documented
2.5-3.0 hours in adults; in renal impairment, half-life is prolonged (up to 6 hours).
Terminal elimination half-life is 8.0-12.0 hours (mean 10 h) in normal renal function; prolonged to up to 40 hours in severe renal impairment.
Renal: approximately 70-80% as unchanged drug and metabolites; fecal: 5-10%.
Renal excretion: approximately 40% unchanged; hepatic metabolism (CYP2D6) with biliary/fecal elimination of metabolites; total clearance 0.15 L/h/kg.
Category C
Category A/B
Alpha-2 Agonist
Alpha-2 Agonist